Home

search

Subjectguide
Journals
Books / Serials / Multimedia
Services
Services

Login for Subscribers
Logout

Sitemap
Help
Contacts


Logo






Vol. 48, No. 1, 2005   

Free Abstract     Article (References)     Article (PDF 131 KB)     

Prevention of Occurrence and Recurrence of Human Hepatocarcinogenesis
Guest Editors: Soo Ryang Kim, Kobe; Okio Hino, Tokyo; Masatoshi Kudo, Osaka


Paper

Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma
Updated Analysis of the Long-Term Follow-Up Data
Koji Takai, Masataka Okuno, Ichiro Yasuda, Rie Matsushima-Nishiwaki, Takahiro Uematsu, Hisashi Tsurumi, Yoshimune Shiratori, Yasutoshi Muto, Hisataka Moriwaki

Department of Gastroenterology, Gifu University School of Medicine, Gifu, Japan

Address of Corresponding Author

Intervirology 2005;48:39-45 (DOI: 10.1159/000082093)


 goto top of page Key Words

  • Lectin-reactive alpha-fetoprotein
  • Chemoprevention
  • Clonal deletion
  • Protein induced by vitamin K absence or antagonist-II
  • Retinoid

 goto top of page Abstract

Oral administration with acyclic retinoid, a synthetic vitamin A analog, for a limited period of 12 months (48 weeks) prevented the development of second primary hepatocellular carcinoma (HCC) and also improved the survival of patients who underwent curative treatments of the initial tumor. Following that randomized controlled study reported in 1996 and 1999, we have continued to follow up the patients by medical imaging and blood chemical analyses, and found that the preventive effect of acyclic retinoid lasted up to 199 weeks after randomization (or 151 weeks after completion of retinoid administration). The retinoid's effect was not mediated by reduction in hepatic necro-inflammation since no significant decrease in serum aminotransferase activity was seen in the retinoid group. Such observation seems quite distinct from the cancer-preventive mechanism of interferon, a potent immunopreventive agent for HCC. We have also shown here the reduction by the retinoid in serum levels of lectin-reactive alpha-fetoprotein (AFP-L3) and protein induced by vitamin K absence or antagonist-II (PIVKA-II), both of which indicate the presence of latent HCC cells. These results suggest that acyclic retinoid may delete such malignant clones before they expand to clinically detectable tumors and thereby inhibited second primary HCC. Once such latent clones are eradicated, it may well take at least several years for the next cancer clone to arise clinically. This may possibly explain a reason for the long-term effect of the retinoid even after the limited period of administration.

Copyright © 2005 S. Karger AG, Basel


 goto top of page Author Contacts

Hisataka Moriwaki, MD
Department of Gastroenterology
Gifu University School of Medicine
Gifu 501-1194 (Japan)
Tel./Fax +81 58 230 6313, E-Mail hmori@cc.gifu-u.ac.jp


 goto top of page Article Information

Number of Print Pages : 7
Number of Figures : 4, Number of Tables : 2, Number of References : 21

 
Journal Home
Journal Content
Guidelines
Editorial Board
Aims and Scope
Subscriptions
Medline Abstract (ID 15785088)
Download Citation
Cited In



This journal is part of the second subject package of the Karger

Journal Archive Collection

Information on packages (PDF)
Free sample issues


For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.





copyright  © 2009 S. Karger AG, Basel